Sex-specific associations of matrix metalloproteinases in Alzheimer’s disease

Table 2 CSF MMP/TIMP levels in CU A−, CU A+, MCI-AD and AD dementia patients

	CU A−	CU A+	MCI-AD	AD dementia	χ²/F (df)	P (η²)
MMP-2 (ng/mL)	47.1 (8.3)	44.2 (9.9)	45.9 (9.0)	43.6 (10.8)	2.45 (3)	0.06
MMP-3 (pg/mL)	232.6 (127.3)	197.8 (129.7)	227.7 (115.6)	250.1 (143.6)	2.43 (3)	0.23
MMP-10 (pg/mL)	16.5 (12.3)	15.4 (16.4)	24.0 (13.6)^a,b	28.4 (20.1)^{a, b}	38.2	< 0.01^c
MMP-12 (pg/mL)	4.0 (4.9)	3.1 (4.1)	2.4 (3.8)	2.7 (3.6)	2.50	0.48^c
TIMP-1 (ng/mL)	61.1 (13.8)	57.2 (14.1)	58.2 (10.2)	59.4 (15.0)	0.68 (3)	0.57
TIMP-2 (ng/mL)	68.1 (8.4)	65.2 (10.2)	72.4 (9.2)^{a, b}	71.8 (9.9)^{a, b}	6.08 (3)	< 0.01 (0.05)
TIMP-3 (ng/mL)	16.4 (1.2)	15.9 (1.3)	16.2 (1.2)	16.3 (1.3)	1.21 (3)	0.31
TIMP-4 (ng/mL)	1.6 (0.4)	1.4 (0.5)	1.7 (0.4)^b	1.6 (0.4)	2.55 (3)	0.06

P-values are given for comparisons between all four groups using ANOVA, unless otherwise specified. Significant differences in bold
^aSignificantly different from the CU A− group; ^bSignificantly different from the CU A+ group; ^cKruskal–Wallis test. A+: biomarkers positive for Aβ pathology, AD Alzheimer’s disease, ANOVA analysis of variance, CSF cerebrospinal fluid, CU cognitively unimpaired, MCI mild cognitive impairment, MMP matrix metalloproteinase, TIMP tissue inhibitor of matrix metalloproteinase

ISSN: 2042-6410